Multi-center, Double-blind, Parallel-group, Randomized, Placebo-controlled, Three Doses, 40-week Extension to Studies ID-078A301 and ID-078A302 to Assess the Long Term Safety and Tolerability of ACT-541468 in Adult and Elderly Subjects With Insomnia Disorder
Phase of Trial: Phase III
Latest Information Update: 14 Feb 2019
At a glance
- Drugs Nemorexant (Primary)
- Indications Insomnia
- Focus Adverse reactions; Registrational
- Sponsors Idorsia Pharmaceuticals
- 06 Nov 2018 Planned initiation date (Estimated date of first participant enrollement) changed from 20 Oct 2018 to 20 Nov 2018.
- 06 Nov 2018 Status changed from not yet recruiting to recruiting.
- 09 Oct 2018 Planned initiation date changed from 28 Sep 2018 to 20 Oct 2018.